IGC Pharma

As of 2023, the estimated number of Americans living with Alzheimer's disease was 6.7 million. However, a lesser-known subsection of Alzheimer's is Agitation in dementia from Alzheimer's Disease (AAD). Recent research suggests that up to 76% of individuals with Alzheimer’s also suffer from...

In a massive stride towards Alzheimer’s treatment, IGC Pharma (NYSE:IGC) recently revealed promising interim results for their pioneering drug, IGC-AD1, aimed at mitigating agitation in Alzheimer’s patients. This breakthrough is a beacon of hope for millions affected by this...

Circle March 20 on your calendars! Starting at 10:25 a.m. EST Wednesday, the Benzinga Virtual Healthcare Summit 2024 is the place to be. Imagine a digital room buzzing with the likes of Beachbody’s Mark Goldston, Autonomix Medical’s Lori Bisson, and IGC Pharma’s Ram Mukunda (NYSE:...

IGC Pharma, Inc. (IGC), a leading cannabinoid-based formulation developer, has expanded its Phase 2 clinical trial for IGC-AD1, a natural THC-based investigational drug for Alzheimer's disease, to the University of Puerto Rico network. IGC is dedicated to developing advanced cannabinoid-based...